地舒单抗对妊娠相关骨质疏松症严重病例骨密度的影响
本文报告一例妊娠相关骨质疏松症(PLO)伴L1和L4椎体骨折患者,产后接受地舒单抗联合维生素D和钙治疗。治疗18个月后腰椎、股骨颈和全髋骨密度分别增加32.2%、13.0%和11.5%,无新发骨折;停药后第二次妊娠期间骨密度较治疗峰值下降,但仍高于基线且无新骨折。
要点
- 地舒单抗产后治疗18个月使腰椎骨密度增加32.2%,无新发骨折。
- 停药后第二次妊娠期间骨密度较峰值下降但仍高于基线,无新骨折。
- 地舒单抗或为PLO患者避免双膦酸盐胎儿风险的可选方案。
核心结论
- 地舒单抗产后治疗可显著提高PLO患者骨密度并降低后续骨折风险,停药后第二次妊娠期间骨密度下降但仍高于基线且无新发骨折。
研究设计与样本
- 单例病例报告,患者为PLO伴L1和L4椎体骨折,产后接受地舒单抗联合每日3000IE维生素D和1000mg钙治疗。
主要发现
- 治疗18个月后腰椎、股骨颈和全髋骨密度分别增加32.2%、13.0%和11.5%,无新发骨折。
- 停药后第二次妊娠期间骨密度较治疗峰值分别下降-8.8%、-6.9%和-7.0%,但仍显著高于基线且无新骨折。
关键数值与推荐
- PLO估计发病率为0.4/100,000。
- 地舒单抗治疗18个月后腰椎骨密度增加32.2%,股骨颈增加13.0%,全髋增加11.5%。
- 第二次妊娠后骨密度较治疗峰值下降:腰椎-8.8%,股骨颈-6.9%,全髋-7.0%。
临床怎么用
- 对于有再生育计划的PLO患者,地舒单抗产后治疗可在停药后妊娠期间维持骨密度高于基线并避免新发骨折。
局限性
- 单例病例报告,证据级别低,结果需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pregnancy and lactation-associated osteoporosis (PLO) with predominantly subsequent vertebral fracture is a rare but severe disease with an estimated incidence of 0.4 in 100,000. In the past, patients with PLO have been predominantly treated with oral and i.v. bisphosphonates to reduce subsequent fracture risk. Hereby, the use of bisphosphonates in premenopausal women is controversial, as bisphosphonates know to persist in bone for many years and can be exposed and circulate in maternal serum and subsequently pass the placenta barrier and may have a detrimental effect on fetal bone health. Here we report the effects of denosumab on the bone mineral density (BMD) and subsequent fracture risk in PLO. In this case presentation, denosumab was administered postpartum with 3000 IE vitamin D and 1000 mg of calcium daily in a patient with PLO and vertebral fracture of L1 and L4. After 18 months of treatment with denosumab, we could demonstrate a clinical significant increase of BMD at the lumbar spine, femoral neck, and total hip of 32.2%, 13.0%, and 11.5% respectively with no further subsequent fractures. As the patient had regular menstrual cycles and considered a further pregnancy, denosumab treatment was terminated and soon a second pregnancy occurred. After the second pregnancy, BMD decreased at the lumbar spine, femur neck, and total hip by -8.8%, -6.9%, and -7.0% respectively compared to the maximum values during treatment with denosumab, but was still significantly higher compared to baseline levels with no further fractures.
引用
- Stumpf U, Kraus M, Hadji P, et al. Influence of denosumab on bone mineral density in a severe case of pregnancy-associated osteoporosis. Osteoporos Int. 2021. PMID: 34041561. doi:10.1007/s00198-021-06008-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。